A Phase 2 Study of EMD 121974 (Cilengitide, NSC 707544) in Patients With Metastatic Melanoma

Trial Profile

A Phase 2 Study of EMD 121974 (Cilengitide, NSC 707544) in Patients With Metastatic Melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Cilengitide (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 19 Dec 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 02 Jun 2012 Results published in Melanoma Research.
    • 02 Jun 2010 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top